Health Santé

Canada Canada
Health Products Direction générale des produits
and Food Branch de santé et des aliments

Natural and Non-prescription Health Products Directorate

250 Lanark Avenue
Ottawa, Ontario, K1A 0K9

May 24, 2022

Dossier ID: d215193

Hari Krishna Thirunahari

Regulatory Affairs Advisor
Germiphene Corporation
1379 Colborne Street East
Brantford ON N3T 5M1

SCREENING ACCEPTANCE LETTER

Dear Hari Krishna Thirunahari,

The information and material submitted for the product GAMACIDE3, control number
261778, received with your letter received March 18, 2022, have been screened and found
acceptable for review as a Drug Identification Number Submission.

An invoice for 100% of the total fee will follow. Please note that the total fee charged for
the review of the submission has not been changed following the screening of the submission in
the Natural and Non-prescription Health Products Directorate.

Payment for the fee is due within 30 calendar days from the date of the invoice and is to be
submitted to "Accounts Receivable", Jeanne-Mance Building, 18th Floor, Room 1804B, Address
Locator: 1918B, 161 Goldenrod Driveway, Ottawa, Ontario K1A 0K9. Cheques are to be made
payable to the Receiver General for Canada. If the payment is not received within 30 days, the
Natural and Non-prescription Health Products Directorate will discontinue the review of your
submission.
 You are requested to refer to the Dossier ID number and control number in any
communications related to this submission.

Sincerely,

Shelly Kreker
Regulatory Affairs Specialist
shelly.kreker@hc-sc.gc.ca
Non-prescription Drugs Evaluation Division
Bureau of Product Review and Assessment
Natural and Non-prescription Health
Products Directorate

This document has been signed electronically using the Health Canada docuBridge system.